---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000029"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:38:21.605537+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NovoCure CEO Asaf Danziger to retire Jan 1, 2025; CFO Ashley Cordova appointed CEO

## Summary
- CEO Asaf Danziger, in role since 2002, retires Jan 1, 2025; will remain on board and advise until early 2026.
- CFO Ashley Cordova named CEO effective Jan 1, 2025; she will stay as CFO until successor appointed.
- COO Wilco Groenhuysen resigns effective Oct 1, 2024; Mukund Paravasthu promoted to COO.
- Groenhuysen entered new employment agreement: base salary $615K/yr to Sept 2025 then $120K/yr to Apr 2026.

## SEC filing metadata
- accession: 0001645113-24-000029
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/nvcr-20240830.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000029
- JSON: https://secwatch.observer/filing/0001645113-24-000029.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000029.txt

## Key facts
- Executive change
  Ashley Cordova was appointed as Chief Executive Officer at NovoCure Ltd.
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On September 3, 2024, the Company announced the appointment of Ashley Cordova, age 45, who is currently serving as the Company’s Chief Financial Officer, as the Chief Executive Officer of the Company and its respective direct and indirect subsidiaries and affiliates (together, the “Novocure Group”), effective January 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm
- Executive change
  Wilco Groenhuysen resigned as Senior Advisor at NovoCure Ltd.
  - Action: resigned
  - Role: Senior Advisor
  source text: On September 3, 2024, the Company also announced that Wilco Groenhuysen, the Company’s Chief Operating Officer, resigned effective October 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm
- Executive change
  Asaf Danziger resigned as Senior Advisor at NovoCure Ltd.
  - Action: resigned
  - Role: Senior Advisor
  source text: On September 3, 2024, Asaf Danziger, Chief Executive Officer of NovoCure Limited (the “Company”) resigned from that position effective January 1, 2025 and accepted a new role as Senior Advisor, effective January 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.